



Inflammasome Reporter Cells

All you have to do is ASC

InvivoGen



Human Cord Blood CD4⁺CD25^{hi} Regulatory T Cells Suppress Prenatally Acquired T Cell Responses to *Plasmodium falciparum* Antigens

This information is current as of July 19, 2018.

Maria S. Mackroth, Indu Malhotra, Peter Mungai, Davy Koech, Eric Muchiri and Christopher L. King

J Immunol published online 28 January 2011
<http://www.jimmunol.org/content/early/2011/01/28/jimmunol.1001188>

Supplementary Material <http://www.jimmunol.org/content/suppl/2011/01/28/jimmunol.1001188.8.DC1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Human Cord Blood CD4⁺CD25^{hi} Regulatory T Cells Suppress Prenatally Acquired T Cell Responses to *Plasmodium falciparum* Antigens

Maria S. Mackroth,* Indu Malhotra,* Peter Mungai,* Davy Koech,[†] Eric Muchiri,[‡] and Christopher L. King*[§]

In malaria endemic regions, a fetus is often exposed in utero to *Plasmodium falciparum* blood-stage Ags. In some newborns, this can result in the induction of immune suppression. We have previously shown these modulated immune responses to persist postnatally, with a subsequent increase in a child's susceptibility to infection. To test the hypothesis that this immune suppression is partially mediated by malaria-specific regulatory T cells (T_{regs}) in utero, cord blood mononuclear cells (CBMC) were obtained from 44 Kenyan newborns of women with and without malaria at delivery. CD4⁺CD25^{lo} T cells and CD4⁺CD25^{hi} FOXP3⁺ cells (T_{regs}) were enriched from CBMC. T_{reg} frequency and HLA-DR expression on T_{regs} were significantly greater for Kenyan as compared with North American CBMC ($p < 0.01$). CBMC/CD4⁺ T cells cultured with *P. falciparum* blood-stage Ags induced production of IFN- γ , IL-13, IL-10, and/or IL-5 in 50% of samples. Partial depletion of CD25^{hi} cells augmented the Ag-driven IFN- γ production in 69% of subjects with malaria-specific responses and revealed additional Ag-reactive lymphocytes in previously unresponsive individuals ($n = 3$). Addition of T_{regs} to CD4⁺CD25^{lo} cells suppressed spontaneous and malaria Ag-driven production of IFN- γ in a dose-dependent fashion, until production was completely inhibited in most subjects. In contrast, T_{regs} only partially suppressed malaria-induced Th2 cytokines. IL-10 or TGF- β did not mediate this suppression. Thus, prenatal exposure to malaria blood-stage Ags induces T_{regs} that primarily suppress Th1-type recall responses to *P. falciparum* blood-stage Ags. Persistence of these T_{regs} postnatally could modify a child's susceptibility to malaria infection and disease. *The Journal of Immunology*, 2011, 186: 000–000.

Malaria infection during pregnancy constitutes a major public health problem in malaria-endemic regions of the world. Pregnant women, particularly those in their first pregnancy, are highly susceptible to malaria (1, 2). Malaria during pregnancy can lead to the sequestration of *Plasmodium falciparum*-infected erythrocytes in the placenta through adhesion to molecules such as chondroitin sulfate A (3–5) and is associated with increased risk of maternal anemia, low birth weight, growth retardation, and premature birth (6, 7). The accumulation of infected erythrocytes in the placenta may result in transplacental transport of infected erythrocytes or their soluble components, thereby exposing and sensitizing the fetal immune system to *P. falciparum* Ags (8–12). The reported frequency of malaria blood-stage-specific T and B cell responses in cord blood mononuclear

cells (CBMC) ranges from ~5% to >70% (13–18). The consequences of this prenatal exposure of the infant to *P. falciparum* remain poorly understood.

Several observations indicate that some newborns may become immune tolerant to malaria blood-stage Ags in utero. Epidemiological studies show that offspring of women with placental malaria are more susceptible to *P. falciparum* infection and demonstrate higher parasitemia compared with offspring of women without placental malaria (19–21). Recently, we found that a subset of newborns of women infected with malaria during pregnancy acquired an immune tolerant phenotype, which persisted into childhood, characterized by increased IL-10 production, T cell anergy, and failure of CBMC to produce primarily IFN- γ and IL-2 in response to malaria blood-stage Ags (22). Importantly, these same children had increased risk for malaria infection compared with children who did not acquire this tolerant phenotype. Similar observations have been made for other human parasitic diseases such as lymphatic filariasis and onchocerciasis (23–25).

The mechanistic basis for this tolerant phenotype acquired in utero remains unclear. Possible explanations include clonal deletion of or anergy in malaria-specific T cells (26, 27) due to impaired APC function in cord blood (28–32). Alternatively, in utero exposure to malaria blood-stage Ags may trigger activation and expansion of regulatory T cells (T_{regs}) and/or increased production of immunomodulatory cytokines such as IL-10 or TGF- β (33–35). Recently, several studies have identified expanded populations of CD4⁺ T cells capable of producing IL-10 in cord blood from offspring of women with placental malaria when compared with those without placental malaria (36, 37). In some of these studies, specifically CD4⁺CD25^{hi} cells have been shown to be an important source of IL-10 (36, 38). Depletion of CD4⁺CD25^{hi} T cells from cord blood augmented the IFN- γ production of

*Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH 44106; [†]Kenya Medical Research Institute, Nairobi, Kenya; [‡]Division of Vector Borne Diseases, Ministry of Health, Nairobi, Kenya; and [§]Veterans Affairs Research Service, Cleveland, OH 44106

Received for publication April 12, 2010. Accepted for publication December 21, 2010.

This work was supported by Grant AI064687 from the National Institutes of Health. M.S.M. was partially supported by a fellowship of the German National Merit Foundation.

Address correspondence and reprint requests to Maria S. Mackroth and Christopher L. King, Center for Global Health and Diseases, Case Western Reserve University, WRC 4132, 2103 Cornell Road, Cleveland, OH 44106. E-mail addresses: mariamackroth@gmx.de and cck21@case.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: CBMC, cord blood mononuclear cell; cRPMI, complete RPMI; FMO, fluorescence minus one; MSP, merozoite surface protein; PfPO, *Plasmodium falciparum* phosphoriboprotein P0; T_{eff}, effector T cell; T_{reg}, regulatory T cell.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/\$16.00

CBMC cultures stimulated with either malaria blood-stage Ags or mitogens, suggesting an immunoregulatory function of these cells (36–38). Further characterization indicated an expanded population of CD4⁺CD25⁺FOXP3⁺ T cells after in vitro culture of CBMC with merozoites or staphylococcal enterotoxin B among offspring of mothers with chronic or past placental malaria (37). These studies, however, failed to isolate and fully characterize these T_{regs}. Because activated nonregulatory CD4⁺ T cells can also express high levels of CD25, and FOXP3 expression can be induced in effector T cells (T_{eff}) upon activation in vitro (39), it remains unclear whether these cells are activated or directly suppressive.

In the current study, we focus on the potential role of T_{regs} in the fetal immune response to *P. falciparum* Ags and whether these regulatory cells suppress malaria Ag-driven responses by CD4⁺CD25^{lo} T cells. Newborns who have been exposed and/or sensitized to malaria blood-stage Ags in utero provide a unique opportunity to isolate and further characterize malaria-specific T_{regs} because of the large number of lymphocytes often available in cord blood. Isolation of T_{regs} from *P. falciparum* malaria-infected/exposed newborns, children, or adults has not been previously reported. In this study, we enriched for CD4⁺CD25^{hi} cells, the majority of which express the T_{reg} maker FOXP3, and evaluated their ability to actively suppress both spontaneous and *P. falciparum* blood-stage Ag-specific T_{eff} responses in vitro. We further evaluated the frequency, phenotype, and activation of CD4⁺ T cell subsets among *P. falciparum*-sensitized versus not sensitized Kenyan neonates (born to women with and without malaria at delivery) relative to the frequency and phenotype of those cells in naive North American controls.

Materials and Methods

Study population

Mothers participating in the study delivered their children at Msambweni District Hospital (Kwale District, Coast Province, Kenya), where perennial *P. falciparum* transmission occurs. Umbilical cord blood was collected from full-term newborns immediately after parturition and was anti-coagulated with heparin. Additionally, maternal peripheral blood and placental intervillous blood were obtained for malaria diagnosis as described (15). Full-thickness placental biopsies of ~1 cm square were obtained and stored in 10% buffered formalin. Subsequently, the sections were embedded in paraffin, sectioned, stained with H&E and Giemsa stain, and examined for the presence of malaria parasites in the placenta and/or hemozoin deposits. Control cord blood was obtained from healthy North American newborns delivered at University Hospitals, Cleveland, OH. Ethical approval was obtained from the Human Investigations Institutional Review Boards of University Hospitals (Case Western Reserve University, Cleveland, OH) and the Kenya Medical Research Institute in Nairobi.

Determination of malaria infection status

Plasmodium infections were identified via two methods: 1) blood smear; and 2) a post-PCR oligonucleotide ligation assay. Thick and thin blood smears were stained with 4% Giemsa for 20 min and examined under oil immersion (original magnification ×100). DNA was extracted from 200 μl erythrocyte pellet obtained from fetal cord blood and 200 μl whole maternal intervillous placental blood using Qiagen DNA extraction kits (DNeasy Kit; Qiagen). The post-PCR oligonucleotide ligation assay based on amplification of the small subunit rRNA gene was performed as previously described (40).

Ags and mitogens

Cytokine responses to two *P. falciparum* blood-stage Ags, merozoite surface protein (MSP)-1₄₂ and *P. falciparum* phosphoriboprotein P0 (PfP0), were examined. rMSP-1₄₂ [3D7 allele, the most common allele in the study population (I. Malhotra and C.L. King, unpublished observations)] was provided by Drs. C. Long, S. Singh, and D. Narum (Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD). Three peptides corresponding to N- and C-terminal regions of PfP0 were synthesized and

purified to 70–80% (Chiron, Clayton, Victoria, Australia). The peptides were designated N1 (DNVGSNQMASVRKSLR; codons 33–48), N2 (SV-RKSLRGKATILMGKNT; codons 42–59), and C1 (AKADEPKKKEE-AKKVE; codons 285–299) and correspond to T cell epitopes identified by lymphocyte proliferation responses of immunized mice (41). PHA (Sigma-Aldrich) or anti-CD3/28-coated T cell expander beads (Dyna) were used as positive controls.

Isolation of mononuclear cells

CBMC were isolated within 2 h of collection by standard density gradient centrifugation on Ficoll-Paque (Amersham Biosciences). The overall scheme for cell preparation is shown in Fig. 1. Only freshly isolated CBMC were used in immunomagnetic cell separation steps and cell-culture experiments including suppression experiments. Cord blood samples from which >1.2 × 10⁸ CBMC were obtained (*n* = 44; shown in Table 1) underwent immunomagnetic cell separation to isolate CD4⁺ T cells, monocytes, and CD4⁺CD25^{hi} cells (Fig. 1). If >1.8 × 10⁸ CBMC were isolated, the excess CBMC were immediately cryopreserved (*n* = 5). If <1.2 × 10⁸ CBMC were obtained, they were not used for CD4⁺CD25^{hi} enrichment, and an aliquot of CBMC were cryopreserved. Irrespective of whether cells were used for selection of CD4⁺CD25^{hi}, a small subset of freshly isolated CBMC were resuspended at a density of 10⁹/ml in RPMI 1640 supplemented with 10% pooled human AB serum (Sigma-Aldrich), 4 mM L-glutamine, 25 mM HEPES, and 80 μg/ml gentamicin (complete RPMI [cRPMI]; BioWhittaker, Gathersburg, MD) and cultured with malarial Ags to detect cytokine production and lymphocyte proliferation.

For immunomagnetic cell separation, the remaining CBMC (if >1.2 × 10⁸) were washed and resuspended in MACS buffer (PBS, 2 mmol/l EDTA, and 0.5% BSA).

CD25^{hi} cells were isolated by immunomagnetic positive selection using microbeads directly conjugated to anti-CD25 Abs (Miltenyi Biotec) at 2 μl/10⁷ CBMC as previously described (42). This amount of anti-CD25 is 5-fold lower than the recommended 10 μl by the manufacturer. We did this to ensure selection of only CD25^{hi} cells, those with high expression of CD25. This protocol reduced the recovery of CD25^{hi} cells, but increased enrichment of CD25^{hi}FOXP3⁺ cells.

After the first round of positive selection, the selected CD25^{hi} cells were subjected to a second round of immunomagnetic separation that produced two populations of CD25^{hi} cells: the double positively selected cells, which we designate CD25^{hi++}, and the cells remaining from the first round of positive selection (i.e., those not positively selected in the second round), which we designate CD25^{hi+} (Fig. 1). CD4⁺CD25^{lo} T cells and CD14⁺ monocytes were then isolated from CD25^{hi} diminished CBMC by negative selection using the Isolation Kit II and the CD4⁺ T Cell Isolation Kit II (both Miltenyi Biotec) following the manufacturer's instruction (Fig. 1).

After separation, cell populations were washed and resuspended in cRPMI and immediately used for cell cultures and add-back suppression assays. All samples that underwent the above described immunomagnetic cell separation and were used for suppression assays are listed in Table 1.

In a subset of samples (*n* = 8), freshly isolated cells were directly stained for flow cytometric analysis to verify the purity of isolated cell populations (Fig. 2). CBMC contained 2–3% FOXP3⁺ cells. After one round of magnetic selection, this was reduced by 40–81% in CD25^{hi} diminished CBMC. CD25^{hi+} showed an average enrichment of 62% for FOXP3 positivity (CD25^{hi+}, range 59–70%; *n* = 8). The twice positively selected CD25^{hi++} were further enriched to an average of 76% for FOXP3 positivity (CD25^{hi++}, range 73–80%; *n* = 8).

Cell culture and suppression assay

Cell cultures were performed in round-bottom 96-well microtiter plates on freshly isolated cells. CBMC and CBMC diminished in CD25^{hi} cells were cultured at 1 × 10⁶/ml, and 10⁵ CD4⁺ T cells were cultured with 5 × 10⁴ monocytes per well. CD25^{hi++} or CD25^{hi+} cells were added to CD4⁺ monocyte cultures at different ratios (ratio CD4⁺/CD25^{hi} at 1:0, 1:1, and 1:0.5) to assess suppressive activity of isolated CD25^{hi} populations. Additional medium was added to wells, so that the final volume was 200 μl. Lymphocytes were stimulated in separate cultures under the following conditions: 1) with highly purified MSP-1₄₂ (5 μg/ml, kindly provided by Carole Long and David Narum at Malaria Vaccine Development Unit, National Institutes of Health); 2) with PfP0 N1, N2, and C1 peptides (10 μg/ml); 3) with either anti-CD3/28 beads (one bead/five CD4⁺ T cells) or PHA (10 μg/ml) as a positive control; and 4) with medium alone (negative control). Optimal concentrations had been determined in previous studies and pilot experiments (14, 15). Neutralizing anti-IL-10 and/or anti-TGF-β were added to a subset of samples to assess the role of immunosuppressive cytokines (*n* = 12; samples were selected based on available number of cells). Culture wells containing CD4⁺ T cell/APCs with and without

CD25^{hi++} or CD25^{hi+} cells were supplemented with 1 µg/ml anti-IL-10 (JES3-9D7; BD Biosciences) and/or 1 µg/ml anti-TGF-β (clone MAB 1835; R&D Systems) based on the manufacturer's recommendation. Cultures were set up in triplicate where sufficient cell numbers were available. Due to limitation on samples and number of isolated CD25^{hi} cells, not all tests could be carried out on all samples.

Quantification of cytokines and lymphocyte proliferation

Quantification of the cytokines IFN-γ, IL-13, IL-5, IL-2, IL-6, and IL-10 was performed on culture supernatants collected at 120 h. IFN-γ was measured by ELISA. The Ab pair for cytokine capture and detection (biotinylated) was as follows: M-700A and M-701B (Endogen, Cambridge, MA). IL-5, IL-10, IL-2, IL-6, and IL-13 were measured using a bead-based multicytokine immunoassay (Upstate Luminex kit) following the manufacturer's instruction. The lower limit of detection for the various cytokines that were evaluated ranged from 5–10 pg/ml depending on the cytokine (5 pg/ml for IL-5 and 10 pg/ml for IL-10, IL-2, IL-6, and IL-13). A positive response was scored when the following criterion was fulfilled: for both CBMC and CD4⁺ T cell cultures, an Ag-driven cytokine production that was at least 2-fold greater than that of parallel cultures containing medium alone. If cytokine production was not detectable in the negative control cultures, ≥20 pg/ml for the Ag-specific cytokine production was considered to be a positive response. No *P. falciparum* Ag-driven cytokine response was detected in test cultures of CBMC from 16 healthy North American newborns.

Lymphocyte proliferation was performed as previously described (14). Samples were performed in triplicate. A positive response was a stimulation index (cpm in test sample/cpm in cultures with medium alone) >2.

Flow cytometric analysis

To evaluate the purity of selected cells, isolated cell populations (CBMC, CD25^{hi} diminished CBMC, CD25^{hi++}, CD25^{hi+}, CD4⁺ T cells, and monocytes) from eight donors were washed in FACS buffer (PBS, 2% FBS, and 0.09% sodium azide) directly after cell separation and surface-stained with anti-CD25 (clone MA-251) and anti-CD4 (clone SK3) (both from BD Biosciences). For FOXP3 expression analysis, intranuclear staining was conducted using the anti-human FOXP3 staining kit according to manufacturer's instruction (clone PCH101; eBioscience). Monocyte populations were stained with CD14 (clone M5E2; BD Biosciences). Stained cells were refrigerated at 4°C and read within 12 h on a four-color flow cytometer (FACS scan with additional second diode to allow detection of allophycocyanin staining) at Coast Province General Hospital in Mombasa, Kenya. Assessment of purity could not be undertaken on all the samples due to limited cell numbers, in particular of the CD25^{hi} populations, and very limited access to a flow cytometer in Kenya.

For a broader characterization of CD4⁺ T cells and T_{reg} surface molecules and FOXP3 expression by flow cytometry, liquid nitrogen-stored Kenyan CBMC were transferred to the United States. Based on cytokine responses in cell culture assays and availability of sufficient frozen Kenyan CBMC, 17 samples were selected and grouped as sensitized ($n = 9$) and not sensitized ($n = 8$). Of the selected Kenyan CBMC, 5 samples represented the same individuals used for CD25^{hi} enrichment experiments and suppression assays (numbers 31, 37, 38, 42, and 44, Table I, Supplemental Table I), and 12 samples were chosen from additional frozen CBMC samples from the same population collected in the same time period (Supplemental Table I, samples F1–F12). In addition, nine frozen North American CBMC samples were included in experiments.

Cryopreserved cells were quick-thawed, washed with PBS, and incubated in cRPMI at 37°C for 2 h. Cells were then washed in FACS buffer and surface stained with the following Abs: CD4 (SK3), CTLA-4 (BNI3) (both from BD Biosciences), CD3 (UCHT1), CD45RO (UCHL1), CD25 (BC96), CD127 (eBioRDR5), HLA-DR (LN3), CD62L (DREG56) (all from eBioscience) and intracellularly stained for FOXP3 (clone PCH101; eBioscience). Flow cytometry was performed on an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star). Unstained cells and single stained cells/beads were included in all experiments. Cells were first gated based on forward and side scatter to exclude dead cells and cell debris. For characterization of CD4⁺ T cells and T_{regs}, lymphocytes were first gated for CD3⁺CD4⁺ cells (Fig. 3). The gate in the right panel of Fig. 3 shows designation for CD25⁺CD127^{lo} cells. CD4⁺ T cells and CD4⁺CD25⁺CD127^{lo} cells were further analyzed for expression of CD45RO, CTLA-4, HLA-DR, and CD62L. Fluorescence minus one (FMO) controls were used to define the gates. It is a staining control that employs all reagents used in a flow cytometry assay except for one fluorochrome of interest (termed FMO) to control for the contribution of spectral overlap to the background when using multiple fluorochromes (43, 44).

Statistical analysis

The significance of differences among three groups was assessed using Kruskal-Wallis testing with Dunn's posttesting (GraphPad Software v4.0, GraphPad). For paired comparisons between two groups, Student *t* test was performed on log-transformed data. Correlation analysis was conducted using Pearson's rank-correlation test.

Results

Study population

The criterion for including individual samples from the study population for functional assays was the ability to obtain sufficient number of lymphocytes ($>1.2 \times 10^8$ CBMC) for CD25^{hi} purification ($n = 44$; Table I; see Figs. 1 and 2 for CD25^{hi} purification). Mothers of these offspring were primarily primigravid (22 out of 42, 52%) and secundigravid (10 out of 42, 24%) women. Of 36 mother/infant pairs tested, 8 (22%) women and/or their newborns showed evidence of active or prior malaria infection during pregnancy as determined by blood smear, PCR, and/or placental microscopy at delivery. Twenty-three of 44 (52%) CBMC samples showed recall responses to one or both malaria blood-stage Ags based on lymphocyte proliferation and/or cytokine production (IFN-γ, IL-13, IL-5, IL-6, IL-2, and/or IL-10; Table I, section 1). There was a mixture of Th1- and Th2-type cytokine production by cord blood lymphocytes in response to malaria blood-stage Ags. Sixteen out of 42 samples tested for IFN-γ (38%) produced IFN-γ in response to *P. falciparum* Ags, and 15 of 32 (46%) showed an IL-13 response (Table I, section 1). Four CBMC samples produced IL-5 (numbers 18, 34, 38, and 40). Cytokine concentrations measured for IL-5 were low, between 15 and 44 pg/ml. Of note, we were unable to detect malaria Ag-induced IL-2 at 120 h due to its consumption in 5-d cultures. Only one sample (number 38) produced IL-6. Kenyan newborns whose samples showed ≥1 positive cytokine recall response and/or lymphocyte proliferation to *P. falciparum* Ags were subsequently classified as sensitized (Table I, section 1). The majority of sensitized samples (16 out of 23) produced either multiple cytokines to *P. falciparum* Ag(s) or produced one cytokine in response to both Ags (i.e., samples 21, 39, and 40, Table I, section 1).

Of note, 6 of 8 (75%) CBMC samples from malaria-infected women demonstrated recall responses to malaria blood-stage Ags, whereas CBMC from 13 of 36 (36%) malaria not-infected women also had fetal priming to malaria Ags indicative of prior malaria exposure.

Higher numbers of T_{regs} are observed in cord blood of offspring sensitized or exposed to malaria Ags in utero

To determine whether CBMC from Kenyan newborns sensitized to malarial Ags in utero have increased frequency of memory T cells or lymphocytes with a T_{reg} phenotype, we did the following: first, we classified newborns as sensitized or not sensitized based on cell culture secretion of cytokines in response to *P. falciparum* Ags. A sample was classified as sensitized if at least one positive cytokine response (IFN-γ, IL-13, IL-5, and/or IL-10) was measured. Newborns were classified as not sensitized if none of the cytokine measurements were positive in response to MSP-1 and PfPO (Supplemental Table I). We then examined expression of T_{reg} memory, and activation markers by flow cytometry for: 1) Kenyan newborns sensitized to malaria ($n = 9$); 2) Kenyan newborns not sensitized to malaria ($n = 8$); and 3) healthy North American newborns ($n = 9$).

As expected the overall frequency of CD4⁺ T cells that expressed the memory cell marker, CD4⁺CD45RO⁺ was low in cord blood, 10–12%, and was similar among the three groups (Supplemental Table II). The majority of memory T cells possessed a central

Table I. Study subjects of cell separation and suppression experiments

Sample Identification No. ^a	Parity	Presence of Malaria Infection			Lymphocyte Sensitization to <i>P. falciparum</i> Blood-Stage Ags (net pg/ml)				
		IVPB	CB	Placental Biopsy	IFN- γ	IL-13	IL-10	LP (SI)	Ag Response
Samples that underwent magnetic bead separation and showed cytokine response to <i>P. falciparum</i> Ags (sensitized samples)									
2	Unknown	ND	ND	ND	ND	206	— ^b	2	MSP-1
3	3	ND	ND	ND	296	—	15	2	MSP-1
4	0	ND	ND	ND	—	—	—	2.8	MSP-1
6	1	ND	—	ND	—	66	—	—	MSP-1
9	4	—	—	Chronic	430	—	—	—	PfPO
10	0	—	—	—	132	—	—	—	PfPO
11	3	—	—	—	15	—	35	—	MSP-1
18	0	—	—	Chronic	97	280	128	—	MSP-1/PfPO
21	0	—	—	—	—	168	295	—	PfPO
27	0	—	—	—	—	107	—	—	MSP-1
28	1	—	—	—	39	165	—	ND	MSP-1/PfPO
30	1	—	—	—	46	239	—	ND	PfPO
32	2	—	—	—	—	200	—	ND	PfPO
33	2	—	+	Acute/chronic	25	53	—	ND	MSP-1/PfPO
34	0	—	—	—	118	—	—	ND	PfPO
35	0	—	—	—	244	—	181	ND	MSP-1/PfPO
37 ^c	0	—	—	—	20	20	—	ND	PfPO
38 ^c	0	+	—	—	—	266	—	ND	MSP-1
39	0	—	—	—	72	—	—	ND	MSP-1/PfPO
40	1	+	—	Acute	154	442	186	ND	MSP-1/PfPO
41	0	—	—	ND	445	539	—	ND	MSP-1
43	0	—	—	—	895	420	—	ND	MSP-1/PfPO
44 ^c	0	—	—	Acute/chronic	278	187	—	ND	MSP-1
Remaining samples that underwent magnetic bead separation									
1	Unknown	ND	ND	ND	—	—	—	—	—
5	0	ND	—	ND	—	—	—	—	—
7	0	ND	—	ND	—	ND	ND	—	—
8	0	ND	—	ND	—	ND	ND	—	—
12	0	—	—	—	—	ND	ND	—	—
13	2	—	—	—	—	—	—	—	—
14	2	—	—	—	—	ND	ND	—	—
15	2	—	—	—	—	ND	ND	—	—
16	1	—	—	—	—	ND	ND	—	—
17	0	+	—	—	—	—	—	—	—
19	1	—	—	—	—	ND	ND	—	—
20	1	—	—	—	ND	ND	ND	—	—
22	1	+	—	Acute	—	—	—	—	—
23	0	—	—	—	—	ND	ND	—	—
24	0	—	—	—	—	ND	ND	—	—
25	1	—	—	—	—	ND	ND	—	—
26	0	—	—	—	—	ND	ND	—	—
29	3	—	—	—	—	—	—	ND	—
31 ^c	0	—	—	—	—	—	—	ND	—
36	1	—	—	—	—	—	—	ND	—
42 ^c	4	—	—	—	—	—	—	ND	—

Maternal parity, presence of malaria infection, and cytokine production by CBMC to *P. falciparum* blood-stage Ag from all study subjects undergoing magnetic bead separation and suppression experiments.

^aSample identification numbers correspond to the chronology of sample acquisition.

^b— indicates values considered to be background or zero values.

^cSamples 31, 37, 38, 42, and 44 were also included in flow cytometry experiments to further characterize T cell phenotype (see Supplemental Table I).

CB, cord blood; IVPB, intervillous placental blood; LP, lymphocyte proliferation; ND, not done; SI, stimulation index.

memory phenotype (CD45RO⁺CD62L^{hi}). There was also no difference in HLA-DR and CTLA-4 expression on CD4⁺ T cells among the three groups (Supplemental Table II).


To evaluate the relative proportion of T_{regs} among the three groups, gated CD4⁺ T cells were further gated for a subpopulation associated with a T_{reg} phenotype, CD25⁺CD127^{lo} (gating schema shown in Fig. 3) (45–48).

Although FOXP3 is a more robust marker of T_{regs}, we found intranuclear staining of FOXP3 technically difficult to perform simultaneously with some of our chosen surface markers, such as CTLA-4, CD45RO, and HLA-DR. Therefore, to validate the association of CD25⁺CD127^{lo} with FOXP3⁺ cells, lymphocytes from nine cord blood samples were examined with a reduced panel that included CD4, CD25, CD127, and FOXP3.

FOXP3⁺ cells were mainly found within the CD25⁺CD127^{lo} population. Whereas 69–80% ($n = 9$) of CD4⁺ T cells staining for CD25⁺CD127^{lo} were FOXP3⁺, only 1 to 2% of CD4⁺CD25[−] cells and 4–6% of CD4⁺CD25⁺CD127⁺ cells expressed FOXP3 (see Supplemental Fig. 1 for one representative sample). Conversely, 72–83% of CD4⁺ FOXP3⁺ T cells were CD25⁺CD127^{lo} (data not shown). The percentages of FOXP3 and CD25⁺CD127^{lo} staining CD4⁺ cells were therefore highly correlated ($r^2 = 0.84$, $p < 0.0001$; Supplemental Fig. 1) in CBMC. Together, this suggests that cell populations expressing the markers FOXP3 and CD25⁺CD127^{lo} are very similar and representative of T_{regs}.

Kenyan newborns sensitized in utero to malaria blood-stage Ags had an average of 4.7% of their CD4⁺ cells expressing CD25⁺CD127^{lo} compared with an average of 3.7% and 3.1% of cord

FIGURE 1. Experimental overview and cell separation schema. The flow chart presents an overview of the experimental setup as well as the overall scheme for CBMC cell separation and enrichment of CD25^{hi} cells. Freshly isolated CBMC were used for immunomagnetic bead separation. The first round of enrichment produced CD25^{hi} cells that underwent a second round of separation, generating two different populations: the twice positively selected CD25^{hi++} cells and the remaining cells, referred to as CD25^{hi+}. CD4⁺ T cells and monocytes were further enriched from CD25^{hi} diminished CBMC as described in the *Materials and Methods* section. Flow cytometry was performed on a subset of these isolated cells to demonstrate purity and FOXP3 positivity ($n = 8$). CBMC and isolated lymphocyte fractions were set up for cell culture and add-back experiments. Cryopreserved CBMC were later used for flow cytometric analysis of regulatory cells, memory, and activation marker expression.



blood CD4⁺ cells from not sensitized newborns or unexposed North American newborns, respectively (Fig. 4A). The frequency of CD25⁺CD127^{lo} cells in the malaria-sensitized group was significantly greater compared with North Americans ($p < 0.01$; Fig. 4A). Significantly more CD25⁺CD127^{lo} cells from Kenyan newborns expressed HLA-DR⁺ (0.95%) compared with North American controls (0.32%, $p < 0.01$; Fig. 4B), indicating greater activation or expansion of these T_{regs} in Kenyan newborns (49).

By contrast, there was no difference in CTLA-4 expression among the three groups (mean percentage was 0.24, 0.23, and 0.2% for Kenyan-sensitized, not sensitized, and North Americans, respectively) nor for the memory effector cell phenotype CD45RO⁺CD62L^{hi} (mean percentage was 16, 16.5, and 14.5%) or for the central memory phenotype CD45RO⁺CD62L^{lo} (mean percentage was 7.2, 7.7, and 9.6%).

Effect of CD25^{hi} depletion on recall responses to malaria blood-stage Ags by CBMC

To assess whether CD4⁺CD25^{hi} T cells suppress malaria Ag-induced cytokine production by CBMC, we partially depleted CD25^{hi} T cells from CBMC using a single round of immunomagnetic selection in subjects shown in Table I. Examination of FOXP3⁺CD25^{hi} in CBMC before and after depletion (CBMC versus CD25^{hi} diminished CBMC) showed an average reduction of 64% (range 40–81%, $n = 8$; Fig. 2). Partial depletion of CD4⁺CD25^{hi} augmented the net malaria blood-stage Ag-driven IFN- γ in 11 of 16 malaria-sensitized subjects (previously shown malaria Ag-specific IFN- γ recall response), whereas in the remaining 5 subjects, there was a decrease or no change in IFN- γ release (Fig. 5A). Among the 26 subjects that were not identified as sensitized, partial depletion of CD25^{hi} cells resulted in detection of Ag-driven IFN- γ production in three subjects (Fig. 5B), indicating that the failure to observe Ag-driven cytokine production in some cord blood cells may result from active suppression through T_{regs}. In contrast to IFN- γ , partial depletion of CD4⁺CD25^{hi} resulted in a significant decrease in IL-13 production for seven subjects, no change in four, and an increase in four subjects (data not shown). Comparatively fewer subjects showed malaria Ag-driven IL-5 and IL-10 (Table I). CD4⁺CD25^{hi} cell depletion produced no consistent effect on increased or decreased IL-5 or IL-10 production (data not shown). Thus, CD25^{hi} cells have a variable effect on modulating Ag-driven cytokine production in CBMC, with a generally suppressive effect on malaria Ag-driven Th1-like cytokine production, but not on Th2-type cytokine production (i.e., IL-13 and IL-5).

In cultures with measurable spontaneous cytokine release, partial depletion of CD25^{hi} cells increased IFN- γ levels by 2.2–13.5-fold in 6 subjects, decreased by >50% in 5 subjects, and showed no change in the remaining 31 subjects. By contrast, no





FIGURE 2. Cell separation and T_{reg} isolation. The flow cytometry dot plots show FOXP3⁺ and CD25^{hi} expression on one representative sample of CBMC, CBMC diminished in CD25^{hi}, CD25^{hi++}, and CD25^{hi+} cells after gating for CD4⁺ T cells. Cells were first gated based on forward and side scatter to exclude dead cells and cell debris and then gated for CD4⁺ T cells based on side scatter and expression of CD4. Gates for FOXP3 and CD25 were based on FMO controls. Total of 4.4% of CD4⁺ cells in CBMC expressed FOXP3, which was reduced by ~50% in CD25^{hi} diminished CBMC after one round of CD25 selection. Total of 80% of the CD4⁺ cells in the CD25^{hi++} population were FOXP3⁺ compared with 69% in the CD25^{hi+} population.

FIGURE 3. CD25⁺CD127^{lo} gating schema. Cells were first gated based on forward and side scatter to exclude dead cells and cell debris and then gated for CD4⁺ T cells based on expression of CD4 and CD3. CD4⁺ T cells were further gated for CD25⁺CD127^{lo} cells as shown in the right panel.



subject demonstrated a >2-fold change in spontaneous IL-13, IL-5, and IL-10 production following partial removal of CD25^{hi} cells (data not shown).

Suppressive effects of enriched CD4⁺CD25^{hi} T_{regs} on Ag-driven cytokine production by CD4⁺CD25^{lo} T cells

To directly evaluate the ability of CD4⁺CD25^{hi} T_{regs} to suppress the production of cytokines by malaria Ag-specific T cells from cord blood, we first isolated CD25^{hi} lymphocytes immunomagnetically. We adopted a strategy in which CD25^{hi} cells were positively selected

twice using anti-CD25-coated beads. After two rounds of immunomagnetic separation, we obtained two populations: CD25^{hi++} and CD25^{hi+} cells (Fig. 1). A total of 75–85% of the selected cells were CD4⁺. In the CD25^{hi++} population, 78–85% of the CD4⁺ cells were FOXP3⁺ (Fig. 2). The CD25^{hi+} population (positively selected in the first round of selection, but not retained magnetically in the second round) showed lower levels of purity, with ~68–75% of CD4⁺ cells expressing FOXP3.

Fig. 2 shows the CD25 and FOXP3 expression of a representative sample of CD25^{hi++} and CD25^{hi+} populations, both gated for CD4⁺ cells. Of note, preliminary studies of enriched CD25^{hi++} show low expression of CD127 (data not shown). Cell purity of selected monocytes and CD4⁺ T cells was consistently >90% and >93%, respectively. Cell recovery was generally low, typically between 3 and 8 × 10⁵ CD25^{hi++} cells from a total >1.2 × 10⁸ CBMC. Enriched CD25^{hi++} cells (cultured with CD14 positively selected monocytes, ratio of 2:1 for CD25^{hi++} to monocytes; n = 5) had a phenotype characteristic of T_{regs} (50); they failed to proliferate or produce IL-2 in response to PHA compared with strong




FIGURE 4. Frequency and HLA-DR expression of CD4⁺CD25⁺CD127^{lo} cells is increased in Kenyan neonates. Figures present the percentage of CD4⁺CD25⁺CD127^{lo} cells (A) and CD4⁺CD25⁺CD127^{lo} cells expressing the activation marker HLA-DR (B) in CD4⁺ T cells from *P. falciparum*-sensitized and not sensitized Kenyan and North American newborns. Kruskal-Wallis test with Dunn's posttest comparisons were used to assess the significance of differences (shown in figure). The overall *p* value that includes all three groups for A is *p* = 0.0083 and for B is *p* = 0.0011.




FIGURE 5. Depletion of CD25^{hi} cells enhances IFN- γ responses to *P. falciparum* Ags in some individuals. The effect of partial depletion of CD25^{hi} cells on net malaria blood-stage Ag-driven IFN- γ production from Kenyan CBMC sensitized (A) or not sensitized (B) as evaluated in Table I is shown. The dashed lines represent the geometric mean.

proliferation responses of similarly cultured CD4⁺CD25^{lo} T cells (data not shown). Enriched CD4⁺CD25^{hi++} lymphocytes did, however, spontaneously produce variable amounts of IL-10; four out of seven individuals tested produced from 98–627 pg/ml of IL-10, and one subject secreted 643 pg/ml IL-6. There was no spontaneous production of IL-5, IL-13, or IFN- γ .

To evaluate the suppressive capacity of enriched CD25^{hi++} on CD4⁺CD25^{lo} T cells (subsequently referred to as CD4⁺ T cells), CD4⁺ T cells were cocultured with monocytes alone as APCs or with the addition of an equal number of enriched CD25^{hi++} cells (e.g., a 1:1 ratio plus APCs). T_{regs} were added to cultures in the absence (spontaneous) or presence of malaria blood-stage Ag (Fig. 6). Fifteen subjects' CBMC had detectable spontaneous IFN- γ production, of which nine (60%) showed complete suppression by addition of T_{regs}, four showed partial suppression, and two showed increased IFN- γ production (Fig. 6A; $p = 0.01$). We next examined the effect of adding T_{regs} to cultures in the presence of malaria blood-stage Ags (Fig. 6B, 6C). Fig. 6B illustrates an experiment from one CBMC sample. Of note, because there were insufficient numbers of highly enriched cells to add at a lower ratio, less highly enriched CD25^{hi++} cells (obtained after a single round of positive selection) were added to CD4⁺ cells at 1:1 and 0.5:1 ratio. Often the addition of CD25^{hi++} resulted in complete suppression of malaria Ag-driven IFN- γ , for which levels of suppression decreased in a dose-dependent fashion with the less enriched CD25^{hi+} cells added (Fig. 6B, 6C). Fig. 6C summarizes the results of suppressive effects of T_{regs} on all CBMC showing malaria Ag-induced IFN- γ production. Complete suppression of Ag-driven IFN- γ was observed in 12 of 16 subjects, and 3 had partial suppression. Overall, the addition of CD25^{hi++} produced a mean average suppression of 85% for malaria Ag-driven IFN- γ production by CD4⁺ cells ($p < 0.001$), and with lower numbers of T_{regs} (CD25^{hi+}), the suppression was 70% ($p < 0.05$).

The effect of CD25^{hi++} on suppression of Ag driven IL-13 release was less pronounced than that observed for IFN- γ (Fig. 7). Addition of CD25^{hi++} to CD4⁺ cells in the absence of malaria Ag

failed to suppress spontaneous IL-13 release (CD4⁺ alone, geometric mean = 10, and CD4⁺ with CD25^{hi++} geometric mean = 24; Fig. 7A). Fig. 7B shows an experiment from one CBMC sample. In all subjects with malaria Ag-driven IL-13, 4 of 15 subjects had complete inhibition, 1 showed no inhibition, 1 individual demonstrated an increase in IL-13, and the remaining 9 individuals showed partial suppression (Fig. 7C). The overall mean level of suppression was 61% with highly enriched CD25^{hi++} ($p < 0.05$). Addition of less enriched CD25^{hi+} cells failed to induce significant IL-13 suppression ($p > 0.05$). Although not shown, similar results were observed for malaria Ag-induced IL-5. Thus, CD25^{hi++} T cells showed weaker suppression of Th2-type cytokine production compared with Th1-type responses. Of note, IL-10 production by CD4⁺ T cells was not suppressed by adding CD25^{hi++} cells (data not shown); rather the addition augmented IL-10 production in 5 of 6 subjects showing an IL-10 response to malaria Ags (data not shown).

Suppression of CD4⁺ T cells by T_{regs} is not dependent on IL-10 or TGF- β production

Because some isolated CD25^{hi++} cells from Kenyan newborns produced IL-10, and IL-10 and TGF- β are known to mediate suppression of T cell responses (36, 51–53), we evaluated whether these cytokines from T_{regs} or other IL-10/TGF- β -producing CD4⁺ cells may contribute to the observed immune suppression. The addition of neutralizing anti-IL-10 and/or anti-TGF- β to cultures failed to significantly augment spontaneous IFN- γ production by CD4⁺ cells and continued to suppress CD4⁺ cells' spontaneous IFN- γ production after addition of anti-IL-10/TGF- β (Fig. 8A; $p = 0.03$). With respect to Ag-driven cytokine production, neutralizing Abs to IL-10- and/or TGF- β -augmented malaria Ag-driven IFN- γ in some individuals (Fig. 8B; representative of 2 out of 12 studied) but not others (Fig. 8C; representative of 2 out of 12; the remaining 8 out of 12 did not show any Ag-





FIGURE 6. Cord blood CD25^{hi} T_{regs} suppress spontaneous and *P. falciparum*-Ag-specific IFN- γ response. The figures illustrate the effect of enriched CD25^{hi} cells on suppression of spontaneous (A) and malaria Ag-driven IFN- γ (B, C). B shows an experiment with CBMC from newborn number 3 (Table I) in which CD25^{hi++} and CD25^{hi+} cells are enriched and added back to purified CD4⁺ T cells with APCs. This subject was shown because sufficient CD25^{hi++} cells were available for add back at several ratios. Cultures were performed in triplicate unless there were insufficient cells, and values represent mean + SE. C summarizes the results of subjects for which there was detectable net malaria Ag-driven IFN- γ . Each point represents mean net (Ag-induced minus spontaneous) cytokine production for responders. Lines connect CBMC from the same individual for the three culture conditions indicated. The condition 2 \times CD4⁺/APC was included as an additional control condition. Subsequent add-back experiments are to 1 \times CD4⁺ T cells. Dashed lines (A) and bars (C) in the figures show the geometric mean cytokine production for all individuals. Kruskal-Wallis test with Dunn's posttest comparisons were used to assess the significance of differences (shown in figure). The overall p values that include all three groups for C is $p = 0.0002$.

FIGURE 7. Cord blood CD25^{hi} T_{regs} suppress *P. falciparum*-Ag-specific, but not spontaneous IL-13 response. Enriched CD25^{hi} cells fail to suppress spontaneous IL-13 release from CD4⁺CD25^{lo} T cells (A) but CD25^{hi+} do suppress malaria Ag-driven IL-13 production (B, one individual) and for all malaria-Ag-reactive individuals that produced IL-13 (C). Panels are identical to those described in legend of Fig. 6 with the exception that B shows results from subject 38 in Table I. The overall *p* value (for the three groups) for C is *p* = 0.023, and comparison for degree of suppression of CD4⁺CD25^{hi+} on CD4⁺CD25^{lo} cells is partial and significant at *p* < 0.05 level using the same analysis described in the legend of Fig. 6.



driven cytokine production above background). Importantly, the blocking of endogenous IL-10 and/or TGF- β failed to reverse the suppressive effect of CD4⁺CD25^{hi+} cells on malaria Ag-driven IFN- γ (Fig. 8B, 8C) or IL-13 (data not shown).

Discussion

In humans and other primates a unique maternal–fetal interface develops where the placenta of fetal origin is in direct contact with maternal blood (i.e., hemochorial placenta development). This allows for efficient gas and nutrient exchange and the trans-placental transfer of Abs from maternal to fetal circulation. However, this physiology requires development of immunologic mechanisms whereby the semiallogeneic fetus escapes recognition by the maternal immune system. This requirement provides for the

expression on the placenta of nonclassical MHC class I HLA-G, which stimulates inhibitory receptors on cells of lymphoid and myelomonocytic origin (54, 55). It also selects for the production of immune inhibitory cytokines, PGs, and immunoregulatory T cells (56, 57). The increasing study of CD4⁺CD25⁺FOXP3 T_{regs} in cord blood has shown they are typically immature and not activated compared with those from adult blood, yet they appear to be more suppressive (42, 58–61). When fetal T_{regs} are exposed to nonself-Ags in utero, however, they become critical in the regulation of maternal cell interaction in the fetus, and these cells persist well into childhood (62). Thus, the introduction of exogenous Ags, such as malarial products, into this potent fetal regulatory milieu may heighten stimulation of Ag-specific T_{regs}. In this study, we show the presence of malaria blood-stage Ag-specific




FIGURE 8. Anti-IL-10/anti-TGF- β do not abrogate suppression by CD25^{hi} T_{regs}. Suppressive effects of CD25^{hi+} T_{regs} on spontaneous cytokine release and malarial Ag-induced cytokine production were examined with and without neutralizing anti-IL-10 and anti-TGF- β . A shows the effects of neutralizing anti-IL-10/anti-TGF- β on spontaneous IFN- γ production and suppression by CD25^{hi+} T_{regs} (*n* = 12). Each symbol point represents spontaneous cytokine production for one individual. Bars in A show the geometric mean of spontaneous IFN- γ production for all study samples in this experiment (*n* = 12). The *p* values were determined using paired *t* test of log-transformed data. B and C, Graphs present IFN- γ production by T cells plus or minus T_{regs} and/or neutralizing anti-IL-10/anti-TGF- β as indicated on the x-axis. B shows results from cultures induced with Pfp0 from individual 32 and C from cultures induced with MSP-1 using CBMC from newborn 44 in Table I. Cultures were performed in triplicate unless there were insufficient cells, and values represent mean + SE.

CD4⁺CD25^{hi}FOXP3 T_{regs} in cord blood from newborns of malaria-infected or malaria-exposed women. These cells, when purified, are directly suppressive of CD4⁺CD25^{lo} T cells in a dose-dependent fashion. This suppression is much more potent for Th1 than for Th2-type cytokine production by cord blood cells, consistent with generally Th2 cytokine bias of cord blood lymphocytes (18, 63, 64). IL-10 or TGF- β do not mediate this T_{reg} suppression, consistent with some but not all prior studies (36, 38).

This study differed from prior studies examining T_{regs} in malaria-infected individuals or in cord blood from mothers exposed to malaria in that we directly purified CD4⁺CD25^{hi} regulatory cells. The large amount of lymphocytes collected in some of our cord blood samples allowed such studies, which cannot be routinely performed on peripheral blood samples, particularly in young children. We undertook two rounds of positive selection using a lower concentration of anti-CD25 beads than recommended by the manufacturer, with the aim of preferentially enriching for CD4⁺ T cells that expressed very high levels of CD25. These cells are most strongly associated with a T_{reg} phenotype as determined by the presence of FOXP3. As a consequence of this stringent selection, the number of CD4⁺CD25^{hi} cells recovered was low. This and practical obstacles in the field led to the limitation that not all of the enriched samples were checked for the purity of FOXP3⁺ cells (those checked did show limited variability, however, with 78–85% of CD4⁺ cells being FOXP3⁺). As a consequence, the observed differences in level of suppression with add back among samples may have resulted from differences in FOXP3⁺ enrichment. Another limitation of this purification is that not all T_{regs} have been depleted from whole CBMC. This may account for the failure to augment Ag-driven responses in some subjects following partial depletion. Only a subset of CBMC diminished in CD25^{hi} was measured for the amount of CD4⁺CD25^{hi} depletion, which was highly variable due to the lower number of beads used to remove CD4⁺CD25^{hi}. Therefore, we were unable to accurately associate depletion of CD4⁺CD25^{hi} with the magnitude of Ag-driven IFN- γ .

The enriched CD4⁺CD25^{hi} cells had functional characteristics of T_{regs}. They failed to proliferate or to generate IL-2 with mitogen stimulation and produced variable amounts of IL-10 (47). Of note, retention of functional suppression following enrichment of CD25^{hi} T cells required the use of fresh CBMC and a larger number of available CBMC. This requirement, along with the limited number of enriched cells, precluded detailed phenotypic analysis. Therefore, we did not correlate functional activity with phenotypic expression, a limitation of the study. Enriched T_{regs} suppressed both spontaneous and malaria blood-stage Ag-driven IFN- γ production in a dose-dependent fashion. The observation that enriched T_{regs} suppressed spontaneous IFN- γ in the absence of additional exogenous Ag suggests preactivation to exogenous Ag in utero or by the process of positive selection. However, some enriched T_{regs} that showed only partial suppression in spontaneous cultures completely suppressed Ag-induced IFN- γ production (Fig. 6), suggesting that a subset of T_{regs} is malaria Ag-specific. Furthermore, not all enriched T_{regs} suppressed spontaneous or Ag-induced IFN- γ , supporting the notion of in utero activation in some infants and not others.

Enriched cord blood T_{regs} were much more effective in suppressing Th1-type as compared with Th2-type cytokine production. Enriched T_{regs} consistently failed to inhibit spontaneous IL-13 release, whereas in the same cultures, IFN- γ production was completely suppressed. Similarly, enriched T_{regs} partially suppressed Ag-induced IL-13 production, but to a lesser extent than that of IFN- γ in the same cultures and only at a ratio of CD4⁺CD25^{hi++} to CD4⁺CD25^{lo} of 1:1. Although much data supports the

observation that T_{regs} can suppress Th2-type responses (65, 66), this varies depending on the culture conditions used. Prior studies indicate that enriched CD25⁺ T_{regs} show defective suppression of Th2-type cytokines to birch pollen, but only during the birch pollen season (67). Similarly, Th2 clones were less susceptible to suppression by human thymocyte-derived CD25⁺ T_{regs} compared with Th1 clones (68). The addition of IL-4 or IL-9 could further reduce the suppressive capacity on Th2 cells, but not Th1 lines, supporting the interpretation that Th1 clones respond to primarily IL-2, whereas Th2 cells can respond to other growth factors such as IL-4 and IL-9. This is consistent with one possible mechanism of T_{regs} suppression, in which high expression of CD25, or IL-2R, depletes cultures of IL-2 necessary for cell activation and growth, especially for Th1-type cells, whereas Th2-type cells can respond to other growth factors. This may occur under conditions that produce greater amounts of these additional growth factors (e.g., IL-4 and IL-9), such as during allergy season or in the fetal environment (66, 69, 70). This observation is consistent with our prior observations that newborns who develop a tolerant phenotype in utero show persistent suppression of malaria-specific Th1, but little suppression of malaria-specific Th2-type responses in childhood (22).

Substantial amounts of IL-10 are produced by CBMC in malaria-exposed fetuses (14, 15, 17, 38), which are thought to be important for immunoregulation (36, 38, 71). This can occur both spontaneously and in response to malaria blood-stage Ags, suggesting that expansion of IL-10-producing T cells may be important for modulating malaria Ag-specific immune responses. In malaria-exposed neonates, CD4⁺CD25^{hi} cells appear to be a source of IL-10 (36, 38), and IL-10 has been identified as a key mediator of T_{reg} function (along with TGF- β and IL-35); the extent to which these cytokines mediate suppression by T_{regs} appears to vary greatly in different pathogenic/hemostatic settings (72). The present studies suggest that IL-10 or TGF- β are not important mediators of CD4⁺CD25^{hi}FOXP3⁺ T_{reg}-induced suppression by cord blood following malaria exposure, suggesting that other mechanisms may be involved, such as metabolic disruption of T_{eff} by consumption of locally produced IL-2 as mentioned above or by targeting dendritic cells for suppression. Our observations do show, however, an immunoregulatory role of IL-10 whereby adding anti-IL-10 augmented IFN- γ production in previously unresponsive individuals, which is consistent with previous studies (71). This phenomenon is likely mediated through other T_{reg} subsets.

Two recent studies in adults have shown that FOXP3⁺ T_{regs} are expanded in infected versus noninfected adults as well as exposed versus nonexposed adults (73, 74). Similar to these recent studies in adults, previous studies with cord blood have examined whether T_{regs} are more likely to be obtained from mothers who have evidence of current or prior malaria. The history of prenatal exposure to malaria has been typically surmised by the presence of malaria in the placenta at the time of delivery, either by direct detection of parasites (PCR, blood smear) or histologically. The detection of hemozoin (malaria pigment) in the placenta indicates prior infection, resulting in classification of placental malaria as acute, chronic, or past infection (no evidence of active infection at delivery). Whether this histological classification accurately reflects prenatal exposure to malaria is unknown. Using this criterion, however, one study demonstrated CD4⁺CD25^{hi} T_{regs} are more prevalent in cord blood from offspring of women with placental malaria (36). A second study showed an expansion of CD4⁺CD25⁺FOXP3⁺ cells only after in vitro stimulation with merozoites or staphylococcal enterotoxin B in offspring of women with chronic or past but not active malaria (37). A third study found no association with placental malaria and T_{regs} in cord

blood (38), similar to the lack of association with malaria infection in women for the current study. Because lack of evidence of malaria in the placenta or peripheral blood at delivery does not exclude prior malaria exposure, a better negative control is cord blood cells from newborns living in an area not endemic for malaria. Using this control, we found the proportion of CD4⁺ cells expressing a T_{regs} phenotype was 30–40% higher in cord blood from Kenyans (many of whom have been exposed to malaria), as compared with cord blood from North Americans. More striking is the finding that T_{regs} from Kenyan CBMC were 3-fold more likely to express the activation marker HLA-DR compared with T_{regs} from North American newborns. By contrast, we found no difference in markers on T_{regs} from Kenyan and North American newborns with respect to the memory marker CD45RO, the immunoregulatory marker CTLA-4, or markers suggestive of effector memory (CD45RO⁺CD62L⁻) or central memory (CD45RO⁺CD62L⁺) cells. Together, these observations suggest activation and expansion of T_{regs} in Kenyan newborns exposed to malaria and other parasite Ags in utero. It is likely that only a small subset of T_{regs} are strongly activated at any point, especially to malaria, and they may be difficult to detect by flow cytometry.

In contrast to other studies, we also classified newborns with malaria exposure in utero based on whether they developed recall responses to malaria blood-stage Ags at birth. Such responses could have developed at any time during pregnancy, even if the mother was found to be negative for malaria at delivery. Using this classification, there was a trend toward greater numbers and frequency of activated T_{regs} in cord blood from malaria-sensitized versus nonsensitized children; however, the numbers were too small to show significant differences. This is not surprising for three reasons. First, the nonsensitized offspring may include a putatively tolerant group (i.e., prior malaria exposure) that may have expanded T_{regs}, but lack a conventional Ag recall response (20). Second, using only two purified Ags, MSP-1, and PfP0 in our experiments, it is likely that not all potentially sensitized offspring were detected. Third, T_{regs} may also have been expanded and activated in response to other Ags in utero. Pregnant women living in malaria endemic areas are often coinfecting with various helminth, bacterial, and viral infections that can stimulate immune responses in the fetus.

In our study, suppressive T_{regs} could be isolated from most, but not all newborns, and the suppressive capacity varied among individuals. This observed variation may be related more to differences in purification than real functional differences. Additionally, the proportion of T_{regs} that were malaria specific was difficult to assess. Once T_{regs} are activated either to malaria or other Ags, however, they can suppress nonspecifically (75, 76). It is unlikely that T_{reg} differences in cord blood could have arisen from maternal contamination because we have previously shown in our population significant admixture occurs infrequently (10).

What is clear from this and other studies is that T_{regs} are expanded and activated in cord blood from newborns living in malaria endemic areas, either as a consequence of in utero exposure to malaria or to Ags of chronic blood-borne infections found in pregnant women in these areas. A better understanding of T_{regs} function in utero will require the use of more accurate biomarkers for their presence and function, as well as a better way to correlate timing of malaria infection during pregnancy.

Recent studies show that T_{regs} can modify susceptibility to disease (77, 78) and contribute to whether the host immune responses are protective or pathological in response to infection with *P. falciparum* parasites (73, 79–82). The nature of the initial exposure to malaria Ags likely affects the potentially diverse roles

assumed by T_{regs} in malaria infection. For some individuals, this first experience appears to occur in utero (10, 12, 14, 17, 83, 84). This may have an important impact on the subsequent development of an individual's immune response to malaria and potentially to other Ags. How this prenatal exposure shapes the subsequent immune response is only now beginning to be studied. The current and several previous studies indicate that the generation of T_{regs} is an important component of the response; however, further study of factors that determine how T_{regs} are generated in utero, how they function, and whether they persist into infancy and childhood as a reservoir of preactivated regulatory cells is needed. Such studies are important, as increasing efforts are made to intensively control malaria during pregnancy, such as with prophylactic drugs and through immunization programs once an effective malaria vaccine emerges. The subsequent lack of exposure to malarial Ags in utero will surely affect malarial morbidity and mortality in childhood, but in ways that we are only beginning to understand.

Acknowledgments

We thank Ephraim Odek Adel, Elton Mzungu Kafwani, Kefar Wambua, and Charles NgaNga for technical help in conduction of the immunological assays. We also thank the maternity nurses at Msambweni Hospital for help with collection of cord blood and the women residing in the Msambweni area for participation in the study.

Disclosures

The authors have no financial conflicts of interest.

References

1. Steketee, R. W., B. L. Nahlen, M. E. Parise, and C. Menendez. 2001. The burden of malaria in pregnancy in malaria-endemic areas. *Am. J. Trop. Med. Hyg.* 64(1-2, Suppl): 28–35.
2. Breman, J. G., A. Egan, and G. T. Keusch. 2001. The intolerable burden of malaria: a new look at the numbers. *Am. J. Trop. Med. Hyg.* 64(1-2, Suppl): iv–vii.
3. Fried, M., and P. E. Duffy. 1996. Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta. *Science* 272: 1502–1504.
4. Duffy, P. E., and M. Fried. 2003. *Plasmodium falciparum* adhesion in the placenta. *Curr. Opin. Microbiol.* 6: 371–376.
5. Maubert, B., N. Fievet, G. Tami, C. Boudin, and P. Deloron. 2000. Cytoadherence of *Plasmodium falciparum*-infected erythrocytes in the human placenta. *Parasite Immunol.* 22: 191–199.
6. Uneke, C. J. 2007. Impact of placental *Plasmodium falciparum* malaria on pregnancy and perinatal outcome in sub-Saharan Africa: II: effects of placental malaria on perinatal outcome; malaria and HIV. *Yale J. Biol. Med.* 80: 95–103.
7. Desai, M., F. O. ter Kuile, F. Nosten, R. McGready, K. Asamoah, B. Brabin, and R. D. Newman. 2007. Epidemiology and burden of malaria in pregnancy. *Lancet Infect. Dis.* 7: 93–104.
8. Jakobsen, P. H., F. N. Rasheed, J. N. Bulmer, M. Theisen, R. G. Ridley, and B. M. Greenwood. 1998. Inflammatory reactions in placental blood of *Plasmodium falciparum*-infected women and high concentrations of soluble E-selectin and a circulating P. falciparum protein in the cord sera. *Immunology* 93: 264–269.
9. Malhotra, I., A. Dent, P. Mungai, E. Muchiri, and C. L. King. 2005. Real-time quantitative PCR for determining the burden of *Plasmodium falciparum* parasites during pregnancy and infancy. *J. Clin. Microbiol.* 43: 3630–3635.
10. Malhotra, I., P. Mungai, E. Muchiri, J. J. Kwiek, S. R. Meshnick, and C. L. King. 2006. Umbilical cord-blood infections with *Plasmodium falciparum* malaria are acquired antenatally in Kenya. *J. Infect. Dis.* 194: 176–183.
11. Falade, C., O. Mokuolu, H. Okafor, A. Orogade, A. Falade, O. Adedoyin, T. Ogunu, M. Aisha, D. H. Hamer, and M. V. Callahan. 2007. Epidemiology of congenital malaria in Nigeria: a multi-centre study. *Trop. Med. Int. Health* 12: 1279–1287.
12. Redd, S. C., J. J. Wirima, R. W. Steketee, J. G. Breman, and D. L. Heymann. 1996. Transplacental transmission of *Plasmodium falciparum* in rural Malawi. *Am. J. Trop. Med. Hyg.* 55(1, Suppl): 57–60.
13. Fievet, N., P. Ringwald, J. Bickii, B. Dubois, B. Maubert, J. Y. Le Hesran, M. Cot, and P. Deloron. 1996. Malaria cellular immune responses in neonates from Cameroon. *Parasite Immunol.* 18: 483–490.
14. Malhotra, I., A. N. Wamachi, P. L. Mungai, E. Mzungu, D. Koech, E. Muchiri, A. M. Moormann, and C. L. King. 2008. Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of *Plasmodium falciparum* MSP(33). *J. Immunol.* 180: 3383–3390.
15. Malhotra, I., P. Mungai, E. Muchiri, J. Ouma, S. Sharma, J. W. Kazura, and C. L. King. 2005. Distinct Th1- and Th2-Type prenatal cytokine responses to *Plasmodium falciparum* erythrocyte invasion ligands. *Infect. Immun.* 73: 3462–3470.

16. King, C. L., I. Malhotra, A. Wamachi, J. Kioko, P. Mungai, S. A. Wahab, D. Koech, P. Zimmerman, J. Ouma, and J. W. Kazura. 2002. Acquired immune responses to *Plasmodium falciparum* merozoite surface protein-1 in the human fetus. *J. Immunol.* 168: 356–364.
17. Brustoski, K., M. Kramer, U. Möller, P. G. Kremsner, and A. J. Luty. 2005. Neonatal and maternal immunological responses to conserved epitopes within the DBL-gamma3 chondroitin sulfate A-binding domain of *Plasmodium falciparum* erythrocyte membrane protein 1. *Infect. Immun.* 73: 7988–7995.
18. Metenou, S., A. L. Suguitan, Jr., C. Long, R. G. Leke, and D. W. Taylor. 2007. Fetal immune responses to *Plasmodium falciparum* antigens in a malaria-endemic region of Cameroon. *J. Immunol.* 178: 2770–2777.
19. Mutabingwa, T. K., M. C. Bolla, J. L. Li, G. J. Domingo, X. Li, M. Fried, and P. E. Duffy. 2005. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. *PLoS Med.* 2: e407.
20. Schwarz, N. G., A. A. Adegnika, L. P. Breitling, J. Gabor, S. T. Agnandji, R. D. Newman, B. Lell, S. Issifou, M. Yazdanbakhsh, A. J. Luty, et al. 2008. Placental malaria increases malaria risk in the first 30 months of life. *Clin. Infect. Dis.* 47: 1017–1025.
21. Le Hesran, J. Y., M. Cot, P. Personne, N. Fievet, B. Dubois, M. Beyemé, C. Boudin, and P. Deloron. 1997. Maternal placental infection with *Plasmodium falciparum* and malaria morbidity during the first 2 years of life. *Am. J. Epidemiol.* 146: 826–831.
22. Malhotra, I., A. Dent, P. Mungai, A. Wamachi, J. H. Ouma, D. L. Narum, E. Muchiri, D. J. Tisch, and C. L. King. 2009. Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. *PLoS Med.* 6: e1000116.
23. Elson, L. H., A. Days, M. Calvoña, W. Paredes, E. Araujo, R. H. Guderian, J. E. Bradley, and T. B. Nutman. 1996. In utero exposure to *Onchocerca volvulus*: relationship to subsequent infection intensity and cellular immune responsiveness. *Infect. Immun.* 64: 5061–5065.
24. Malhotra, I., P. L. Mungai, A. N. Wamachi, D. Tisch, J. M. Kioko, J. H. Ouma, E. Muchiri, J. W. Kazura, and C. L. King. 2006. Prenatal T cell immunity to *Wuchereria bancrofti* and its effect on filarial immunity and infection susceptibility during childhood. *J. Infect. Dis.* 193: 1005–1013.
25. Malhotra, I., J. H. Ouma, A. Wamachi, J. Kioko, P. Mungai, M. Njzovu, J. W. Kazura, and C. L. King. 2003. Influence of maternal filariasis on childhood infection and immunity to *Wuchereria bancrofti* in Kenya. *Infect. Immun.* 71: 5231–5237.
26. Gammon, G., K. Dunn, N. Shastri, A. Oki, S. Wilbur, and E. E. Sercarz. 1986. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. *Nature* 319: 413–415.
27. Gammon, G. M., A. Oki, N. Shastri, and E. E. Sercarz. 1986. Induction of tolerance to one determinant on a synthetic peptide does not affect the response to a second linked determinant. Implications for the mechanism of neonatal tolerance induction. *J. Exp. Med.* 164: 667–672.
28. Schwartz, R. H. 2003. T cell anergy. *Annu. Rev. Immunol.* 21: 305–334.
29. Taylor, S., and Y. J. Bryson. 1985. Impaired production of gamma-interferon by newborn cells in vitro is due to a functionally immature macrophage. *J. Immunol.* 134: 1493–1497.
30. Mahnke, K., J. Knop, and A. H. Enk. 2003. Induction of tolerogenic DCs: 'you are what you eat'. *Trends Immunol.* 24: 646–651.
31. Mahnke, K., Y. Qian, J. Knop, and A. H. Enk. 2003. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. *Blood* 101: 4862–4869.
32. Jonuleit, H., E. Schmitt, G. Schuler, J. Knop, and A. H. Enk. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. *J. Exp. Med.* 192: 1213–1222.
33. Rieger, M., and I. Hilgert. 1977. The involvement of a suppressor mechanism in neonatally induced allograft tolerance in mice. *J. Immunogenet.* 4: 61–67.
34. Fernandez, M. A., F. K. Puttur, Y. M. Wang, W. Howden, S. I. Alexander, and C. A. Jones. 2008. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. *J. Immunol.* 180: 1556–1564.
35. Rainsford, E., and D. J. Reen. 2002. Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. *Br. J. Haematol.* 116: 702–709.
36. Brustoski, K., U. Moller, M. Kramer, F. C. Hartgers, P. G. Kremsner, U. Krzych, and A. J. Luty. 2006. Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental *Plasmodium falciparum* infection. *J. Infect. Dis.* 193: 146–154.
37. Flanagan, K. L., A. Halliday, S. Burl, K. Landgraf, Y. J. Jagne, F. Noho-Konteh, J. Townend, D. J. Miles, M. van der Sande, H. Whittle, and S. Rowland-Jones. 2010. The effect of placental malaria infection on cord blood and maternal immunoregulatory responses at birth. *Eur. J. Immunol.* 40: 1062–1072.
38. Bisseye, C., M. van der Sande, W. D. Morgan, A. A. Holder, M. Pinder, and J. Ismaili. 2009. *Plasmodium falciparum* infection of the placenta impacts on the T helper type 1 (Th1)/Th2 balance of neonatal T cells through CD4+(+)CD25(+) forkhead box P3(+) regulatory T cells and interleukin-10. *Clin. Exp. Immunol.* 158: 287–293.
39. Allan, S. E., S. Q. Crome, N. K. Crellin, L. Passerini, T. S. Steiner, R. Bacchetta, M. G. Roncarolo, and M. K. Levings. 2007. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. *Int. Immunol.* 19: 345–354.
40. Mehlotra, R. K., K. Lorry, W. Kastens, S. M. Miller, M. P. Alpers, M. Bockarie, J. W. Kazura, and P. A. Zimmerman. 2000. Random distribution of mixed species malaria infections in Papua New Guinea. *Am. J. Trop. Med. Hyg.* 62: 225–231.
41. Chatterjee, S., S. Singh, R. Sohoni, V. Kattige, C. Deshpande, S. Chiplunkar, N. Kumar, and S. Sharma. 2000. Characterization of domains of the phosphoriboprotein P0 of *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* 107: 143–154.
42. Godfrey, W. R., D. J. Spoden, Y. G. Ge, S. R. Baker, B. Liu, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter. 2005. Cord blood CD4(+)CD25(+) derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. *Blood* 105: 750–758.
43. Roederer, M. 2001. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. *Cytometry* 45: 194–205.
44. Roederer, M. 2002. Compensation in flow cytometry. *Curr. Protoc. Cytom.* Chapter 1: Unit 1.14.
45. Liu, W., A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. Gingeras, B. Fazekas de St Groth, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J. Exp. Med.* 203: 1701–1711.
46. Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. *J. Exp. Med.* 203: 1693–1700.
47. Shevach, E. M. 2001. Certified professionals: CD4(+)CD25(+) suppressor T cells. *J. Exp. Med.* 193: F41–F46.
48. Baecher-Allan, C., J. A. Brown, G. J. Freeman, and D. A. Hafler. 2001. CD4+ CD25high regulatory cells in human peripheral blood. *J. Immunol.* 167: 1245–1253.
49. Baecher-Allan, C., E. Wolf, and D. A. Hafler. 2006. MHC class II expression identifies functionally distinct human regulatory T cells. *J. Immunol.* 176: 4622–4631.
50. Stephens, L. A., C. Mottet, D. Mason, and F. Powrie. 2001. Human CD4(+) CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. *Eur. J. Immunol.* 31: 1247–1254.
51. Belkaid, Y. 2008. Role of Foxp3-positive regulatory T cells during infection. *Eur. J. Immunol.* 38: 918–921.
52. Maynard, C. L., and C. T. Weaver. 2008. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. *Immunol. Rev.* 226: 219–233.
53. Wohlfert, E., and Y. Belkaid. 2008. Role of endogenous and induced regulatory T cells during infections. *J. Clin. Immunol.* 28: 707–715.
54. Hunt, J. S., and D. L. Langat. 2009. HLA-G: a human pregnancy-related immunomodulator. *Curr. Opin. Pharmacol.* 9: 462–469.
55. Hunt, J. S., D. K. Langat, R. H. McIntire, and P. J. Morales. 2006. The role of HLA-G in human pregnancy. *Reprod. Biol. Endocrinol.* 4(Suppl 1): S10.
56. Koch, C. A., and J. L. Platt. 2007. T cell recognition and immunity in the fetus and mother. *Cell. Immunol.* 248: 12–17.
57. Trowsdale, J., and A. G. Betz. 2006. Mother's little helpers: mechanisms of maternal-fetal tolerance. *Nat. Immunol.* 7: 241–246.
58. Wing, K., A. Ekmark, H. Karlsson, A. Rudin, and E. Suri-Payer. 2002. Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. *Immunology* 106: 190–199.
59. Cupedo, T., M. Nagasawa, K. Weijer, B. Blom, and H. Spits. 2005. Development and activation of regulatory T cells in the human fetus. *Eur. J. Immunol.* 35: 383–390.
60. Wing, K., P. Larsson, K. Sandström, S. B. Lundin, E. Suri-Payer, and A. Rudin. 2005. CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses. *Immunology* 115: 516–525.
61. Takahata, Y., A. Nomura, H. Takada, S. Ohga, K. Furuno, S. Hikino, H. Nakayama, S. Sakaguchi, and T. Hara. 2004. CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. *Exp. Hematol.* 32: 622–629.
62. Mold, J. E., J. Michaëlsson, T. D. Burt, M. O. Muench, K. P. Beckerman, M. P. Busch, T. H. Lee, D. F. Nixon, and J. M. McCune. 2008. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. *Science* 322: 1562–1565.
63. Zaghouani, H., C. M. Hoeman, and B. Adkins. 2009. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. *Trends Immunol.* 30: 585–591.
64. Forsthuber, T., H. C. Yip, and P. V. Lehmann. 1996. Induction of TH1 and TH2 immunity in neonatal mice. *Science* 271: 1728–1730.
65. Ozdemir, C., M. Akdis, and C. A. Akdis. 2009. T regulatory cells and their counterparts: masters of immune regulation. *Clin. Exp. Allergy* 39: 626–639.
66. Pace, L., C. Pioli, and G. Doria. 2005. IL-4 modulation of CD4+CD25+ T regulatory cell-mediated suppression. *J. Immunol.* 174: 7645–7653.
67. Grindebacke, H., K. Wing, A. C. Andersson, E. Suri-Payer, S. Rak, and A. Rudin. 2004. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergies during birch pollen season. *Clin. Exp. Allergy* 34: 1364–1372.
68. Cosmi, L., F. Liotta, R. Angeli, B. Mazzinghi, V. Santarlasci, R. Manetti, L. Lasagni, V. Vanini, P. Romagnani, E. Maggi, et al. 2004. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. *Blood* 103: 3117–3121.
69. Pace, L., S. Rizzo, C. Palombi, F. Brombacher, and G. Doria. 2006. Cutting edge: IL-4-induced protection of CD4+CD25- Th cells from CD4+CD25+ regulatory T cell-mediated suppression. *J. Immunol.* 176: 3900–3904.
70. Scheffold, A., J. Hübn, and T. Höfer. 2005. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. *Eur. J. Immunol.* 35: 1336–1341.
71. Brustoski, K., U. Möller, M. Kramer, A. Petelski, S. Brenner, D. R. Palmer, M. Bongartz, P. G. Kremsner, A. J. Luty, and U. Krzych. 2005. IFN-gamma and

- IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated *Plasmodium falciparum* malaria. *J. Immunol.* 174: 1738–1745.
72. Vignali, D. A., L. W. Collison, and C. J. Workman. 2008. How regulatory T cells work. *Nat. Rev. Immunol.* 8: 523–532.
 73. Minigo, G., T. Woodberry, K. A. Piera, E. Salwati, E. Tjitra, E. Kenangalem, R. N. Price, C. R. Engwerda, N. M. Anstey, and M. Plebanski. 2009. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. *PLoS Pathog.* 5: e1000402.
 74. Finney, O. C., D. Nwakanma, D. J. Conway, M. Walther, and E. M. Riley. 2009. Homeostatic regulation of T effector to Treg ratios in an area of seasonal malaria transmission. *Eur. J. Immunol.* 39: 1288–1300.
 75. Shevach, E. M., R. A. DiPaolo, J. Andersson, D. M. Zhao, G. L. Stephens, and A. M. Thornton. 2006. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. *Immunol. Rev.* 212: 60–73.
 76. Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettgenberg, J. Knop, and A. H. Enk. 2001. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. *J. Exp. Med.* 193: 1285–1294.
 77. Torcia, M. G., V. Santarlasci, L. Cosmi, A. Clemente, L. Maggi, V. D. Mangano, F. Verra, G. Bancone, I. Nebie, B. S. Sirima, et al. 2008. Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to *Plasmodium falciparum* malaria. *Proc. Natl. Acad. Sci. USA* 105: 646–651.
 78. Todryk, S. M., P. Bejon, T. Mwangi, M. Plebanski, B. Urban, K. Marsh, A. V. Hill, and K. L. Flanagan. 2008. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. *PLoS ONE* 3: e2027.
 79. Scholzen, A., G. Minigo, and M. Plebanski. 2010. Heroes or villains? T regulatory cells in malaria infection. *Trends Parasitol.* 26: 16–25.
 80. Walther, M., D. Jeffries, O. C. Finney, M. Njie, A. Ebonyi, S. Deininger, E. Lawrence, A. Ngwa-Amambua, S. Jayasooriya, I. H. Cheeseman, et al. 2009. Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe *Plasmodium falciparum* malaria. *PLoS Pathog.* 5: e1000364.
 81. Hansen, D. S., and L. Schofield. 2010. Natural regulatory T cells in malaria: host or parasite allies? *PLoS Pathog.* 6: e1000771.
 82. Finney, O. C., E. M. Riley, and M. Walther. 2010. Regulatory T cells in malaria—friend or foe? *Trends Immunol.* 31: 63–70.
 83. Perrault, S. D., J. Hajek, K. Zhong, S. O. Owino, M. Sichangi, G. Smith, Y. P. Shi, J. M. Moore, and K. C. Kain. 2009. Human immunodeficiency virus co-infection increases placental parasite density and transplacental malaria transmission in Western Kenya. *Am. J. Trop. Med. Hyg.* 80: 119–125.
 84. Tena-Tomás, C., M. K. Bouyou-Akotet, E. Kendjo, M. Kombila, P. G. Kremsner, and J. F. Kun. 2007. Prenatal immune responses to *Plasmodium falciparum* erythrocyte membrane protein 1 DBL-alpha domain in Gabon. *Parasitol. Res.* 101: 1045–1050.

Supplemental figure 1. The relationship of CD25, CD127 and FoxP3 positivity.

CBMC were first gated for CD4⁺ Tcells based on CD3 and CD4 expression as shown in figure

3. CD4⁺ Tcells were subsequently gated for FoxP3, CD25 and CD127 expression.

A) CD25/CD127 dot plot of one representative sample. CD25⁺CD127^{lo} and CD25⁺CD127⁺

populations were gated as indicated. B) The histogram presents the FoxP3 expression of

different subpopulations of CD4⁺ Tcells shown in A. Gray line: fluorescence minus one (FMO)




control to define gate for FoxP3 positivity. Dotted line: CD25⁻ population presenting the two

lower quadrants of dot plot in A. 1.4% of CD25⁻ cells are FoxP3⁺. Dashed line:

CD25⁺CD127⁺ population as gated in A. 4.6% of CD25⁺CD127⁺ cells are FoxP3.

Solid black line: CD25⁺CD127^{lo} cells as gated in A. 71.5% of CD25⁺CD127^{lo} cells are FoxP3⁺.

C) Correlation between FoxP3 and CD25⁺CD127^{lo}

A**B****C**

	Population Name
	FMO control
	CD25 ⁻
	CD25+CD127 ⁺
	CD25+CD127 ^{lo}

Supplemental table I: Study subjects for flow cytometric analysis of CD4+Tcell phenotype and activation status ^a

Sample ID	Parity	Presence of malaria infection			Lymphocyte sensitization to Pf blood stage antigens (net pg/ml)				
		IVPB ^b	CB ^c	Placental Biopsy	IFN γ	IL13	IL5	IL10	antigen response (MSP-1 and/or PfP0)
1) Kenyan newborns sensitized to Pf antigens									
F1	4	- ^d	-	chronic	-	-	-	5000	MSP-1
F2	4	-	-	-	-	55	-	90	MSP-1/PfP0
F3	0	+	-	Acute/chronic	260	360	30	460	MSP-1
F4	2	-	-	-	-	150	-	350	MSP-1/PfP0
F5	3	-	-	-	159	-	-	8000	MSP-1
F6	2	+	-	-	38	140	-	7000	MSP-1
37*	0	-	-	-	20	20	-	-	PfP0
38*	0	+	-	-	-	266	44	-	MSP-1
44*	0	-	-	acute/chr	278	187	-	-	MSP-1
2) Kenyan newborns not sensitized to Pf antigens									
F7	1	-	-	-	-	-	-	-	-
F8	0	+	+	-	-	-	-	-	-
F9	1	-	-	-	-	-	-	-	-
F10	0	-	-	-	-	-	-	-	-
F11	1	-	-	-	-	-	-	-	-
F12	0	-	-	nd	-	-	-	-	-
31*	0	-	-	-	-	-	-	-	-
42*	4	-	-	-	-	-	-	-	-

^a Maternal parity, presence of malaria infection and cytokine production by CBMC to Pf blood stage

antigens from all Kenyan study subjects included in flow cytometry experiments to characterize phenotype and activation status of CD4+ Tcells

^bIVPB=intervillous placental blood; ^cCB = cord blood, ^d the “-“ indicates values considered to be background or zero values

* samples were also included in magnetic bead separation and suppression experiments, samples numbers are identical with sample numbers in table I

Supplemental Table II. Phenotypic characterization of Kenyan cord blood

CD4+Tcells^a

Cellular subsets ^b	Kenyan CBMC		
	(Mean % positives, range)		North American naïve
	Sensitized (N=9)	Not Sensitized (N=8)	CBMC (N=9)
CD4+ T cells			
CD45RO ⁺	10.22 (5.04; 23.16)	11.06 (3.49; 26.6)	11.95 (2.95; 18.7)
CTLA-4 ⁺	0.15 (0.047; 0.24)	0.12 (0.03; 0.2)	0.23 (0.07; 0.3)
HLA-DR ⁺	0.19 (0.04; 0.44)	0.19 (0.09; 0.36)	0.11 (0; 0.24)
CD45RO ⁺ CD62L ^{lo}	3.2 (1.94; 5.3)	3.94 (0.92; 8.09)	3.33 (1.69; 6.41)
CD45RO ⁺ CD62L ^{hi}	7.3 (2.67;17.7)	5.94 (2.72; 18.5)	8.32 (1.29; 12.1)

^a Phenotypic characterization of Kenyan cord blood CD4+Tcells according to whether they generated recall responses (sensitized) or not (not sensitized) to malaria blood stage antigens and North American control cord blood cells

^bCD4+ subsets represent the percent of cells staining with the various markers gated on CD4+ T cells.